| 000 | 01435 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250518080654.0 | ||
| 264 | 0 | _c20200121 | |
| 008 | 202001s 0 0 eng d | ||
| 022 | _a1178-2048 | ||
| 024 | 7 |
_a10.2147/VHRM.S210150 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aManolis, Antonis A | |
| 245 | 0 | 0 |
_aSpotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives. _h[electronic resource] |
| 260 |
_bVascular health and risk management _c2019 |
||
| 300 |
_a571-579 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aClinical Decision-Making |
| 650 | 0 | 4 |
_aDiuretics _xadministration & dosage |
| 650 | 0 | 4 | _aDosage Forms |
| 650 | 0 | 4 | _aDrug Compounding |
| 650 | 0 | 4 |
_aFlavoring Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aHeart Failure _xdiagnostic imaging |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMineralocorticoid Receptor Antagonists _xadministration & dosage |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSpironolactone _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aManolis, Theodora A | |
| 700 | 1 | _aMelita, Helen | |
| 700 | 1 | _aManolis, Antonis S | |
| 773 | 0 |
_tVascular health and risk management _gvol. 15 _gp. 571-579 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2147/VHRM.S210150 _zAvailable from publisher's website |
| 999 |
_c30501932 _d30501932 |
||